Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines

用纳米颗粒封装的蒽环类药物减轻长期心脏毒性

基本信息

项目摘要

Survivors of pediatric cancers disproportionately experience subsequent cardiovascular disease. Pediatric cancer survivors are seven times more likely to die of cardiovascular disease compared to the general population. Commonly used anthracycline chemotherapeutic agents, particularly doxorubicin, have been implicated in late cardiovascular disease in cancer survivors, with cumulative dose being the most important risk factor. Studies have shown that even at lower doses of anthracycline exposure (under 100mg/m2), 30% of patients’ hearts show signs of structural abnormalities 6 to 20 years after diagnosis. Strategies to reduce anthracycline-induced cardiotoxicity, including continuous infusion of liposomal doxorubicin or administration of dexrazoxane have not been approved for pediatric use and are not widely adopted in this patient population. This project seeks to advance the development of a patented Apo-A1 mimetic peptide / fatty acid conjugate that self-assembles into micellar structures termed Myr5A-nanoparticles (Myr5A NPs). Myr5A NPs can encapsulate and deliver therapeutic payloads to cancer cells. The synthetic Apo-A1 mimetic peptide component, like Apo-A1 found in physiologic HDL, functionally engages the scavenger receptor class B type 1 (SR-B1) cell surface receptor, resulting in the transfer Myr5A NP drug payloads into the target cell through selective uptake. The selective uptake process is not endosomally-mediated, resulting in delivery of Myr5A NP payloads directly to the cytoplasm. In addition, highly hydrophobic payloads may be efficiently delivered. Myr5A NPs have exhibited long circulating half-lives in animal studies and would be inexpensive to produce at commercial scale. Previous studies have demonstrated SR-B1 expression in a range of tumor cells, in addition to hepatocytes, steroidogenic tissues, and macrophages. The Yustein Lab at Texas Children’s Hospital has confirmed expression of SR-B1 in Ewing sarcoma and other pediatric sarcomas. Based on these observations, we hypothesize that agents encapsulated in Myr5A NPs will selectively target Ewing sarcoma cells with high expression of SR-B1 and spare normal tissues with low SR-B1 expression, such as the heart and kidneys. To test this hypothesis, the Aune Lab will work collaboratively with the Yustein Lab at Texas Children’s Hospital and Qana Therapeutics to evaluate the expression of key DNA damage markers induced by Myr5A NPs loaded with novel anthracyclines (AD198 and valrubicin) in EWS cell lines and cardiac cells in vitro. In addition, we will simultaneously evaluate the antitumor efficacy and cardiac toxicity profile of these agents in vivo, using a unique model developed by the Aune lab to study anthracycline-induced cardiotoxicity. This project will facilitate collection of critical preclinical data by this collaborative group that will lay the foundation for a collaborative clinical trial supported by academia, industry and advocacy groups. Further clinical development could yield a new therapeutic entity that improves outcomes and long-term quality of life for Ewing’s sarcoma patients and other pediatric cancer patients.
儿童癌症的幸存者不成比例地经历随后的心血管疾病。儿科 癌症幸存者死于心血管疾病的可能性是普通人的七倍 人口。常用的蒽环类化疗药物,特别是阿霉素,已被 与癌症幸存者的晚期心血管疾病有关,其中累积剂量是最重要的 风险因素。研究表明,即使在较低剂量的蒽环类药物暴露(低于 100mg/m2)下,30% 的 患者的心脏在诊断后 6 至 20 年内出现结构异常的迹象。减少策略 蒽环类药物引起的心脏毒性,包括持续输注脂质体阿霉素或施用 右雷佐生尚未被批准用于儿科,也没有在该患者群体中广泛采用。 该项目旨在推进专利 Apo-A1 模拟肽/脂肪酸缀合物的开发 自组装成胶束结构,称为 Myr5A 纳米颗粒(Myr5A NP)。 Myr5A NP 可以 封装治疗有效负载并将其递送至癌细胞。合成的 Apo-A1 模拟肽 成分,如生理 HDL 中发现的 Apo-A1,在功能上与 B 类清道夫受体 1 型结合 (SR-B1) 细胞表面受体,导致 Myr5A NP 药物有效负载通过 选择性吸收。选择性摄取过程不是内体介导的,导致 Myr5A NP 的递送 有效负载直接进入细胞质。此外,可以有效地递送高度疏水性的有效负载。 Myr5A NP 在动物研究中表现出较长的循环半衰期,并且生产成本低廉 商业规模。先前的研究已经证明 SR-B1 在一系列肿瘤细胞中表达,此外 肝细胞、类固醇生成组织和巨噬细胞。德克萨斯儿童医院的尤斯坦实验室 证实 SR-B1 在尤文肉瘤和其他儿童肉瘤中表达。 基于这些观察,我们假设封装在 Myr5A NP 中的药物将选择性地靶向 SR-B1高表达的尤因肉瘤细胞,而保留SR-B1低表达的正常组织,例如 如心脏和肾脏。为了验证这一假设,Aune 实验室将与 Yustein 实验室合作 德克萨斯儿童医院和 Qana Therapeutics 评估关键 DNA 损伤标记物的表达 由负载新型蒽环类药物(AD198 和戊柔比星)的 Myr5A NP 在 EWS 细胞系和心脏中诱导 体外细胞。此外,我们将同时评估其抗肿瘤功效和心脏毒性特征 这些药物在体内,使用 Aune 实验室开发的独特模型来研究蒽环类药物诱导的 心脏毒性。该项目将促进该合作小组收集关键的临床前数据,这将 为学术界、工业界和倡导团体支持的协作临床试验奠定基础。 进一步的临床开发可能会产生一种新的治疗实体,从而改善结果和长期质量 尤文氏肉瘤患者和其他儿童癌症患者的生命。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORY J. AUNE其他文献

GREGORY J. AUNE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORY J. AUNE', 18)}}的其他基金

Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
  • 批准号:
    10195941
  • 财政年份:
    2021
  • 资助金额:
    $ 19.77万
  • 项目类别:
BRCA1 and its cofactor in chemotherapy-associated cardiotoxicity
BRCA1 及其辅助因子在化疗相关心脏毒性中的作用
  • 批准号:
    8814679
  • 财政年份:
    2015
  • 资助金额:
    $ 19.77万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了